MedTrace Logo

Rectal Indomethacin to Prevent Post ESWL-pancreatitis

NCT02797067 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1370

Last updated 2022-05-26

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether rectal indomethacin reduces the incidence of post-ESWL pancreatitis.

Conditions

Interventions

DRUG

indomethacin suppository

100mg rectal indomethacin 30min before ESWL

DRUG

Glycerin Suppository

30min before ESWL

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Zhuan Liao, MD · Changhai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2019-07-31
Completion
2021-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02797067 on ClinicalTrials.gov